Principal Financial Group
MTNB icon

Principal Financial Group’s Matinas BioPharma MTNB Stock Holding History

Principal Financial Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-202
Closed -$8K – 2293
2018
Q1 		$8K Buy
+202
New +$10.7K ﹤0.01% 2206

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Principal Financial Group's MTNB Position: Q2 2018 in Review

Principal Financial Group sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 202 shares — an estimated $8K sold.

Principal Financial Group first reported a position in MTNB in Q1 2018 and held it in 1 quarter. The position peaked at $8K in Q1 2018. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

  • Principal Financial Group reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
  • Principal Financial Group sold 202 Matinas BioPharma shares in Q2 2018, an estimated $8K.
  • Principal Financial Group first reported a position in Matinas BioPharma in Q1 2018 and held it in 1 quarter.
  • Principal Financial Group's Matinas BioPharma position peaked at $8K in Q1 2018.
  • 39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Principal Financial Group's 13F filing for Q2 2018, filed 13 Aug 2018.